Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10967713 | Vaccine | 2012 | 8 Pages |
Abstract
⺠Adults â¥40 years of age are commonly hypo-responsive to licensed HBV vaccines. ⺠HBsAg-1018 ISS elicits earlier, higher and longer lasting antibody than Engerix-B. ⺠2 doses of HBsAg-1018 ISS provides superior protection over 3 doses of Engerix-B. ⺠HBsAg-1018 ISS was well tolerated with a similar safety profile as Engerix-B. ⺠HBsAg-1018 ISS may be more effective in hypo-responsive populations.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Benjamin P. Sablan, Dong Joon Kim, Nina G. Barzaga, Wan Cheng Chow, Mong Cho, Sang Hoon Ahn, Seong Gyu Hwang, Ji Hyun Lee, Hamid Namini, William L. Heyward,